Briefing documents released ahead of Friday's meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) suggest Acelrx Pharmaceuticals Inc. might have better luck the second time around with its sublingual 30-mcg tablet version of sufentanil given by way of a non-invasive, single-dose applicator.